Eurofins-Cerep SA
Eurofins-Cerep SA provides various drug discovery services to pharmaceutical, biopharmaceutical, and biotechnology companies France and internationally. The company's research services include compound management, and high-throughput screening and profiling. The company was formerly known as Cerep SA and changed its name to Eurofins-Cerep SA in June 2014. Eurofins-Cerep SA was founded in 1989 and… Read more
Eurofins-Cerep SA - Asset Resilience Ratio
Eurofins-Cerep SA (ALECR) has an Asset Resilience Ratio of 6.56% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2018)
This chart shows how Eurofins-Cerep SA's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Eurofins-Cerep SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €5.55 Million | 6.56% |
| Total Liquid Assets | €5.55 Million | 6.56% |
Asset Resilience Insights
- Limited Liquidity: Eurofins-Cerep SA maintains only 6.56% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Eurofins-Cerep SA Industry Peers by Asset Resilience Ratio
Compare Eurofins-Cerep SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for Eurofins-Cerep SA (2000–2018)
The table below shows the annual Asset Resilience Ratio data for Eurofins-Cerep SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | -0.67% | €-237.72K | €35.26 Million | +28.92pp |
| 2017-12-31 | -29.59% | €-8.93 Million | €30.18 Million | -22.22pp |
| 2016-12-31 | -7.37% | €-1.91 Million | €25.94 Million | +15.31pp |
| 2015-12-31 | -22.67% | €-5.71 Million | €25.18 Million | -24.86pp |
| 2014-12-31 | 2.18% | €500.00K | €22.90 Million | -9.40pp |
| 2013-12-31 | 11.59% | €3.23 Million | €27.89 Million | -11.39pp |
| 2012-12-31 | 22.97% | €6.96 Million | €30.28 Million | -4.19pp |
| 2011-12-31 | 27.17% | €8.89 Million | €32.72 Million | +3.61pp |
| 2010-12-31 | 23.56% | €8.46 Million | €35.90 Million | -12.21pp |
| 2009-12-31 | 35.77% | €15.85 Million | €44.31 Million | +0.59pp |
| 2008-12-31 | 35.19% | €19.32 Million | €54.91 Million | +3.14pp |
| 2007-12-31 | 32.04% | €20.10 Million | €62.73 Million | +31.62pp |
| 2006-12-31 | 0.42% | €321.00K | €76.37 Million | -9.48pp |
| 2005-12-31 | 9.90% | €8.29 Million | €83.65 Million | -7.68pp |
| 2004-12-31 | 17.59% | €11.23 Million | €63.87 Million | -20.56pp |
| 2003-12-31 | 38.14% | €19.55 Million | €51.24 Million | +1.01pp |
| 2002-12-31 | 37.14% | €17.72 Million | €47.72 Million | -2.14pp |
| 2001-12-31 | 39.27% | €16.06 Million | €40.90 Million | +13.61pp |
| 2000-12-31 | 25.66% | €6.07 Million | €23.67 Million | -- |